Cargando…

Clinical Outcomes and Safety of Apatinib Mesylate in the Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer in Patients Who Progressed After Standard Therapy and Analysis of the KDR Gene Polymorphism

PURPOSE: This study investigated the clinical outcomes and safety of apatinib mesylate in the treatment of advanced non-squamous non-small cell lung cancer (NSCLC) in patients who progressed after standard therapy, and analyzed the kinase insert domain receptor (KDR) gene polymorphism. METHODS: A to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Zi-Zheng, Zhao, Li-Fen, Zuo, Jing, Fan, Zhi-Song, Wang, Long, Wang, Yu-Dong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6982468/ https://www.ncbi.nlm.nih.gov/pubmed/32021302 http://dx.doi.org/10.2147/OTT.S222985

Ejemplares similares

Influence of KDR Genetic Variation on the Efficacy and Safety of Patients with Chemotherapy Refractory Metastatic CRC Who Received Apatinib Treatment
por: Bai, Ming, et al.
Publicado: (2021)

Apatinib mesylate tablet in the treatment of advanced malignant melanoma
por: Yang, Lingge, et al.
Publicado: (2018)

Apatinib treatment for KIT- and KDR-amplified angiosarcoma: a case report
por: Yang, Lishu, et al.
Publicado: (2018)

A single-arm, prospective study of apatinib mesylate plus pemetrexed in patients of advanced non-squamous non-small cell lung cancer after failure of previous chemotherapy
por: Dong, Shuang, et al.
Publicado: (2022)

Apatinib Mesylate Inhibits the Proliferation and Metastasis of Epithelioid Malignant Peritoneal Mesothelioma In Vitro and In Vivo
por: Yang, Zhi-Ran, et al.
Publicado: (2020)

Case report of apatinib mesylate treatment in rare advanced tracheal adenoid cystic carcinoma
por: Wang, Hongmei
Publicado: (2017)

Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma
por: Lu, Bin, et al.
Publicado: (2019)

Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma
por: Zhao, Jian, et al.
Publicado: (2019)

Efficacy and safety of apatinib treatment for advanced esophageal squamous cell carcinoma
por: Li, Jianqiang, et al.
Publicado: (2017)

Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer
por: Gao, Guanghui, et al.
Publicado: (2022)

The efficacy and safety of Apatinib in the treatment of advanced non-small cell lung cancer: A retrospective trial
por: Wang, Jijin, et al.
Publicado: (2022)

Combination of apatinib and docetaxel in treating advanced non-squamous non-small cell lung cancer patients with wild-type EGFR: a multi-center, phase II trial
por: Song, Yong, et al.
Publicado: (2020)

Apatinib Mesylate in the treatment of advanced progressed lung adenocarcinoma patients with EGFR-TKI resistance —A Multicenter Randomized Trial
por: Fang, Ping, et al.
Publicado: (2019)

Effects of Apatinib Mesylate Monotherapy on the Incidence of Adverse Reactions and Immune Function in Patients with Breast Cancer after Radical Mastectomy
por: Lin, Sen, et al.
Publicado: (2022)

The Role of VEGF and KDR Polymorphisms in Moyamoya Disease and Collateral Revascularization
por: Park, Young Seok, et al.
Publicado: (2012)

Efficacy and Safety of Apatinib in the Treatment of Postoperative Recurrence of Fibrosarcoma
por: Ma, Huiwen, et al.
Publicado: (2020)

Apatinib as non-first-line treatment in patients with Intrahepatic Cholangiocarcinoma
por: Mao, Jinzhu, et al.
Publicado: (2021)

Salvage treatment with apatinib for advanced non-small-cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2017)

Efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy: An observational study
por: Tian, Zhichao, et al.
Publicado: (2019)

Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma
por: Yuan, Shumin, et al.
Publicado: (2022)

Clinical Effect of Apatinib Mesylate Tablets Combined with Paclitaxel Concurrent Radiotherapy and Chemotherapy in the First-Line Treatment of Locally Advanced Nasopharyngeal Carcinoma
por: Zhan, Dechao, et al.
Publicado: (2022)

The polymorphism and the geographical distribution of the knockdown resistance (kdr) of Anopheles sinensis in the Republic of Korea
por: Kang, Seunghyun, et al.
Publicado: (2012)

Determination of VEGFR-2 (KDR) 604A>G Polymorphism in Pancreatic Disorders
por: Pădureanu, Vlad, et al.
Publicado: (2017)

Liver progenitor cell and KDR
por: Han, Songyan, et al.
Publicado: (2014)

Potential Role of Targeting KDR and Proteasome Inhibitors in the Therapy of Esophageal Squamous Cell Carcinoma
por: Zhang, Ling, et al.
Publicado: (2020)

Camrelizumab and Apatinib Combined with Radiotherapy Is Effective in Advanced Oligometastatic Non-Small-Cell Lung Cancer
por: Ye, Wei, et al.
Publicado: (2022)

Efficacy and safety of apatinib alone or apatinib plus paclitaxel/docetaxel versus paclitaxel/docetaxel in the treatment of advanced non‐small cell lung cancer: A meta‐analysis
por: Li, Zhe, et al.
Publicado: (2021)

Implication of KDR Polymorphism rs2071559 on Therapeutic Outcomes and Safety of Postoperative Patients with Gastric Cancer Who Received S-1-Based Adjuvant Chemotherapy: A Real-World Exploratory Study
por: Meng, Lei, et al.
Publicado: (2023)

NRP-1 and KDR polymorphisms are associated with survival time in patients with advanced gastric cancer
por: Zhuo, Yue-Jian, et al.
Publicado: (2019)

Study of Silver Nanoparticles Sensitized Fluorescence and Second-Order Scattering of Terbium(III)-Pefloxacin Mesylate Complex and Determination of Pefloxacin Mesylate
por: Li, Aiyun, et al.
Publicado: (2014)

Safety of apatinib plus S-1 for advanced solid tumor as palliative treatment
por: Chen, Siying, et al.
Publicado: (2021)

Efficacy and Safety of Apatinib in Patients with Recurrent Glioblastoma
por: Lin, Hao, et al.
Publicado: (2023)

Imatinib Mesylate-Induced Hyperpigmentation of the Nose and Palate
por: Song, Hyo Sang, et al.
Publicado: (2014)

Safety and Efficacy of Low-Dosage Apatinib Monotherapy in Advanced Lung Squamous-Cell Carcinoma: A Prospective Cohort Study
por: Geng, Qian, et al.
Publicado: (2020)

The Safety and Efficacy of Apatinib Treatment in Addition to Concurrent Chemoradiotherapy in Patients with Nonoperative Locally Advanced Esophageal Squamous Cell Carcinoma
por: Hu, Lijun, et al.
Publicado: (2020)

Gene polymorphisms of VEGF and KDR are associated with initial fast peritoneal solute transfer rate in peritoneal dialysis
por: Qian, Yue, et al.
Publicado: (2022)

A Study Of Efficacy And Safety With Apatinib Or Apatinib Combined With Chemotherapy In Recurrent/advanced Ovarian Cancer Patients
por: Yang, Mi, et al.
Publicado: (2019)

Efficacy and Safety of Apatinib Treatment for Patients with Advanced Intrahepatic Cholangiocarcinoma
por: Lin, Guohe, et al.
Publicado: (2020)

EGFR exon 20 insertion mutation in advanced thymic squamous cell carcinoma: Response to apatinib and clinical outcomes
por: Yudong, Su, et al.
Publicado: (2018)

Apatinib plus chemotherapy for non-metastatic osteosarcoma: a retrospective cohort study
por: Wang, Jiaqiang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_me145eksee7003crqjkmbqt8ni